Mechanism of action
Hydrochlorothiazide inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron. This transporter is responsible for reabsorbing approximately 5-10% of filtered sodium. By blocking sodium reabsorption, HCTZ increases sodium and water excretion in the urine, reducing plasma volume and cardiac output.
The antihypertensive effect occurs in two phases. Initially, blood pressure decreases due to reduced plasma volume and decreased cardiac output. With chronic use, plasma volume returns toward normal, but peripheral vascular resistance decreases, maintaining the antihypertensive effect through mechanisms that are not fully understood but may involve reduced vascular smooth muscle calcium and altered sodium content in vessel walls.
Thiazides increase calcium reabsorption in the distal tubule, leading to hypercalcemia. The mechanism involves increased basolateral calcium-sodium exchange and enhanced calcium reabsorption in the proximal tubule due to volume contraction. This property makes thiazides useful in preventing calcium kidney stones.
Potassium loss occurs because increased sodium delivery to the collecting duct enhances sodium reabsorption via epithelial sodium channels (ENaC), creating a lumen-negative potential that drives potassium secretion. This mechanism explains the development of hypokalemia and the rationale for combining thiazides with potassium-sparing diuretics or ACE inhibitors.
- Thiazides inhibit the Na-Cl cotransporter in the distal convoluted tubule
- Cause hypokalemia, hypercalcemia, hyperglycemia, hyperlipidemia, hyperuricemia (hyperGLUC)
- Ineffective when GFR <30 mL/min; switch to loop diuretics in renal failure
- Increase calcium reabsorption; useful for calcium nephrolithiasis prevention
- Thiazide-induced hypokalemia increases digoxin toxicity risk
- Reduce lithium clearance, increasing lithium toxicity risk
- First-line for hypertension, especially in elderly and African Americans
- Paradoxically reduce urine output in nephrogenic diabetes insipidus via volume contraction
Indications
Hypertension: Hydrochlorothiazide is a first-line agent for essential hypertension, either as monotherapy or in combination with other antihypertensives. Multiple trials have demonstrated reduction in cardiovascular morbidity and mortality. It is particularly effective in elderly patients and African American populations.
Edema: HCTZ is used to manage edema associated with heart failure, hepatic cirrhosis, nephrotic syndrome, and chronic kidney disease. It is less potent than loop diuretics and generally reserved for mild to moderate fluid overload.
Nephrogenic diabetes insipidus: Paradoxically, thiazides reduce urine volume in nephrogenic diabetes insipidus by inducing mild volume depletion, which increases proximal tubule reabsorption of water and decreases water delivery to the collecting duct.
Calcium nephrolithiasis: Thiazides reduce urinary calcium excretion and are used to prevent recurrent calcium oxalate and calcium phosphate kidney stones in patients with hypercalciuria.
Osteoporosis prevention: The calcium-retaining effect of thiazides may reduce bone loss and fracture risk in postmenopausal women, though this is not a primary indication.
Pharmacokinetics
Hydrochlorothiazide is administered orally and has variable absorption (65-75% bioavailability). Absorption may be decreased by food and cholestyramine. Peak plasma concentrations occur 1-2.5 hours after ingestion, with onset of diuretic action within 2 hours.
The drug is not metabolized and is excreted unchanged by the kidneys via glomerular filtration and active tubular secretion. The elimination half-life is approximately 6-15 hours, allowing once-daily dosing. Duration of action is 6-12 hours.
HCTZ does not cross the blood-brain barrier significantly but does cross the placenta and is excreted in breast milk. Volume of distribution is approximately 4 L/kg, and plasma protein binding is 40-70%.
Renal impairment significantly affects thiazide efficacy. When creatinine clearance falls below 30 mL/min, thiazides become progressively less effective because the drug cannot reach its site of action in adequate concentrations. Loop diuretics are preferred in advanced renal impairment.
Adverse effects
Electrolyte and metabolic disturbances
Hypokalemia is the most common adverse effect, resulting from increased potassium excretion in the collecting duct. Severe hypokalemia can cause muscle weakness, cramps, arrhythmias, and potentiation of digoxin toxicity. Risk is dose-dependent and increased with concurrent use of other potassium-wasting drugs.
Hyponatremia occurs due to increased sodium excretion combined with continued water intake. Elderly women are at particularly high risk. Severe hyponatremia can cause confusion, seizures, and coma.
Hypercalcemia results from increased distal tubule calcium reabsorption. While usually mild, it can unmask hyperparathyroidism or contribute to nephrocalcinosis.
Hypomagnesemia develops from increased urinary magnesium losses and can contribute to hypokalemia and cardiac arrhythmias.
Metabolic alkalosis occurs because volume contraction stimulates aldosterone secretion and hydrogen ion excretion in the collecting duct, while potassium depletion shifts hydrogen ions intracellularly.
Hyperglycemia results from multiple mechanisms including decreased insulin secretion, increased insulin resistance, and hypokalemia-induced impairment of insulin release. Thiazides can precipitate diabetes in predisposed individuals or worsen glycemic control in diabetics.
Hyperlipidemia: Thiazides can increase total cholesterol, LDL cholesterol, and triglycerides, though the clinical significance remains debated.
Hyperuricemia occurs because thiazides compete with uric acid for tubular secretion and volume contraction enhances proximal tubule uric acid reabsorption. This can precipitate gout attacks in susceptible patients.
Other adverse effects
- Photosensitivity: Increased risk of sunburn and rash with sun exposure
- Sexual dysfunction: Erectile dysfunction in men, reduced libido
- Pancreatitis: Rare but serious complication
- Hypersensitivity reactions: Rash, urticaria, rarely Stevens-Johnson syndrome or toxic epidermal necrolysis
- Hematologic: Thrombocytopenia, leukopenia, agranulocytosis (rare)
- Acute myopia and angle-closure glaucoma: Rare idiosyncratic reaction typically occurring within hours to weeks of initiation
Contraindications and warnings
Absolute contraindications include anuria and known hypersensitivity to thiazides or sulfonamide-derived drugs. Patients with documented sulfonamide allergy should use thiazides with caution, though cross-reactivity is debated.
Severe renal impairment (CrCl <30 mL/min) is a relative contraindication because thiazides are ineffective at low GFR. Loop diuretics are preferred in this setting.
Hepatic encephalopathy: Thiazides can precipitate or worsen hepatic encephalopathy in patients with cirrhosis due to electrolyte disturbances and volume depletion.
Pregnancy category B: Thiazides cross the placenta and can cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. They are generally avoided during pregnancy unless benefits clearly outweigh risks. They are not first-line for pregnancy-induced hypertension.
Breastfeeding: HCTZ is excreted in breast milk and may suppress lactation. Use with caution.
Gout: Use cautiously in patients with history of gout due to hyperuricemia risk.
Diabetes mellitus: Monitor glucose closely, as thiazides can worsen glycemic control.
Hypercalcemia or hypokalemia: Avoid in patients with pre-existing electrolyte abnormalities until corrected.
Systemic lupus erythematosus: Thiazides may activate or exacerbate SLE.
Elderly patients are at increased risk of hyponatremia, orthostatic hypotension, and volume depletion. Use lower doses and monitor electrolytes closely.
Drug interactions
Digoxin: Thiazide-induced hypokalemia and hypomagnesemia increase the risk of digoxin toxicity and cardiac arrhythmias. Monitor potassium and magnesium levels closely.
Lithium: Thiazides reduce lithium clearance by promoting proximal tubule lithium reabsorption during volume contraction, increasing the risk of lithium toxicity. Avoid combination if possible; if used together, monitor lithium levels closely and reduce lithium dose.
NSAIDs: Nonsteroidal anti-inflammatory drugs blunt the antihypertensive and diuretic effects of thiazides by inhibiting prostaglandin-mediated renal vasodilation and sodium excretion. They also increase the risk of acute kidney injury when combined with diuretics.
Corticosteroids and ACTH: Increase potassium loss, raising the risk of severe hypokalemia.
ACE inhibitors and ARBs: Combination therapy is common and beneficial for blood pressure control and potassium balance. However, the risk of acute kidney injury increases, especially in volume-depleted patients or those with renal artery stenosis. Monitor renal function and potassium.
Antidiabetic agents: Thiazides may reduce the efficacy of insulin and oral hypoglycemic drugs due to hyperglycemic effects. Dose adjustments may be necessary.
Cholestyramine and colestipol: Bind thiazides in the gut, reducing absorption. Administer thiazides at least 1 hour before or 4-6 hours after bile acid sequestrants.
Alcohol, barbiturates, narcotics: Potentiate orthostatic hypotension.
Antihypertensive drugs: Additive blood pressure lowering effects. Combination therapy is often intentional but requires monitoring for hypotension.
Calcium and vitamin D: May increase the risk of hypercalcemia when combined with thiazides.
Clinical pearls
Thiazides are more effective antihypertensives than loop diuretics for patients with normal renal function because they produce sustained reduction in peripheral vascular resistance. Loop diuretics cause more aggressive volume depletion but less sustained blood pressure reduction.
The classic teaching "thiazides cause hypercalcemia, loops cause hypocalcemia" is a high-yield board concept. Remember that thiazides decrease urinary calcium excretion, making them useful for calcium stone prevention, while furosemide increases calcium excretion and can be used to treat hypercalcemia.
For exam purposes, memorize the metabolic derangements: hypokalemia, hyponatremia, hypercalcemia, hypomagnesemia, hyperglycemia, hyperlipidemia, hyperuricemia. The mnemonic "hyperGLUC" captures the "hyper" abnormalities: Glucose, Lipids, Uric acid, Calcium.
Thiazides are ineffective when GFR falls below 30 mL/min because they must be secreted into the tubular lumen to reach their site of action at the distal convoluted tubule. This is a frequent exam question.
Sulfa allergy is often cited as a contraindication, but true cross-reactivity between sulfonamide antibiotics and sulfonamide diuretics is rare. The concern stems from the sulfonamide moiety present in both drug classes, but the reaction mechanisms differ.
Chlorothiazide is the only thiazide available in IV formulation. Hydrochlorothiazide, chlorthalidone, and indapamide are oral only. Chlorthalidone has a longer half-life (40-60 hours) than hydrochlorothiazide and may be more effective for cardiovascular risk reduction.
In nephrogenic diabetes insipidus, thiazides work paradoxically by inducing mild volume depletion, which enhances proximal tubule water and sodium reabsorption, reducing the volume of fluid reaching the collecting duct. This is a classic board question testing understanding of compensatory mechanisms.
When used for hypertension, the maximal blood pressure reduction with HCTZ occurs at 12.5-25 mg daily. Higher doses provide minimal additional antihypertensive benefit but significantly increase the risk of metabolic side effects. This is why modern guidelines favor lower doses.
Thiazide-induced acute myopia and angle-closure glaucoma is a rare but important adverse effect. Patients present with acute bilateral vision changes, eye pain, and headache within hours to weeks of starting the drug. The mechanism involves ciliary body edema and anterior rotation of the lens-iris diaphragm. Treatment requires immediate drug discontinuation and ophthalmologic evaluation.
Combination pills containing HCTZ with ACE inhibitors, ARBs, or beta-blockers are extremely common in clinical practice. The combination addresses the hypokalemia risk of HCTZ while providing complementary antihypertensive mechanisms.
HyperGLUC: thiazides cause hyperGlycemia, hyperLipidemia, hyperUricemia, hyperCalcemia
Practice questions
1. A 68-year-old woman with hypertension has been taking hydrochlorothiazide 25 mg daily for 3 months. She now presents with muscle weakness and cramping. Laboratory studies show: Na+ 138 mEq/L, K+ 2.9 mEq/L, Cl- 98 mEq/L, HCO3- 32 mEq/L, Ca2+ 10.8 mg/dL. ECG shows flattened T waves and prominent U waves. Which of the following best explains her presentation?
2. A 55-year-old man with heart failure and chronic kidney disease (GFR 25 mL/min/1.73 m²) presents with worsening lower extremity edema. His current medications include lisinopril and metoprolol. The physician considers adding a diuretic. Which of the following is the most appropriate choice?
3. A 72-year-old woman taking digoxin 0.125 mg daily for atrial fibrillation is started on hydrochlorothiazide 25 mg daily for hypertension. Two weeks later, she presents with nausea, vomiting, and visual disturbances. ECG shows frequent premature ventricular contractions. Serum potassium is 2.8 mEq/L and digoxin level is 2.8 ng/mL (therapeutic range 0.5-2.0). Which mechanism best explains the elevated digoxin level?
Frequently asked questions
How does hydrochlorothiazide work?
Hydrochlorothiazide inhibits the sodium-chloride cotransporter in the distal convoluted tubule, blocking sodium and water reabsorption. This increases urine output, reduces plasma volume, and lowers blood pressure. With chronic use, peripheral vascular resistance decreases, providing sustained antihypertensive effects. The drug also increases calcium reabsorption and potassium excretion at the distal nephron.
What are the side effects of hydrochlorothiazide?
Common side effects include hypokalemia, hyponatremia, hyperglycemia, hyperlipidemia, hyperuricemia, and hypercalcemia. Patients may experience dizziness, muscle cramps, weakness, and increased urination. Serious but rare effects include severe electrolyte imbalances, pancreatitis, photosensitivity reactions, and acute angle-closure glaucoma. Thiazides can also precipitate gout attacks and worsen diabetes control. Elderly patients are particularly vulnerable to hyponatremia and orthostatic hypotension.
Is hydrochlorothiazide a controlled substance?
No, hydrochlorothiazide is not a controlled substance. It is a prescription medication but has no potential for abuse or dependence. It is classified as a thiazide diuretic used primarily for hypertension and edema management. Unlike controlled substances such as opioids or benzodiazepines, HCTZ does not produce euphoria or psychological dependence and is not regulated under the Controlled Substances Act.
Hydrochlorothiazide vs furosemide: what is the difference?
Hydrochlorothiazide is a thiazide diuretic acting on the distal convoluted tubule, while furosemide is a loop diuretic acting on the loop of Henle. Furosemide is more potent and effective in severe heart failure and renal impairment (GFR <30), whereas HCTZ is preferred for hypertension in patients with normal kidney function. Thiazides cause hypercalcemia; loops cause hypocalcemia. HCTZ provides better long-term blood pressure control through reduced vascular resistance, while furosemide causes more aggressive diuresis.
Why does hydrochlorothiazide cause hypokalemia?
Hydrochlorothiazide causes hypokalemia by increasing sodium delivery to the collecting duct. The increased sodium reabsorption there creates a lumen-negative electrical gradient that drives potassium secretion into the urine. Additionally, thiazide-induced volume contraction stimulates aldosterone release, which further promotes potassium excretion. This potassium loss can be clinically significant and may require supplementation, dietary modification, or combination with potassium-sparing diuretics or ACE inhibitors to prevent complications like arrhythmias.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: C03AA03
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.